T Sonia Boender1, Cissy M Kityo2, Ragna S Boerma3, Raph L Hamers4, Pascale Ondoa5, Maureen Wellington6, Margaret Siwale7, Immaculate Nankya2, Elizabeth Kaudha2, Alani Sulaimon Akanmu8, Mariette E Botes9, Kim Steegen10, Job C J Calis11, Tobias F Rinke de Wit5, Kim C E Sigaloff4. 1. Amsterdam Institute for Global Health and Development, Department of Global Health, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands Global Child Health Group, Emma Children's Hospital/Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands s.boender@amc.nl. 2. Joint Clinical Research Centre, Kampala, Uganda. 3. Amsterdam Institute for Global Health and Development, Department of Global Health, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands Global Child Health Group, Emma Children's Hospital/Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands. 4. Amsterdam Institute for Global Health and Development, Department of Global Health, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands Department of Internal Medicine, Division of Infectious Diseases, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands. 5. Amsterdam Institute for Global Health and Development, Department of Global Health, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands. 6. Newlands Clinic, Harare, Zimbabwe. 7. Lusaka Trust Hospital, Lusaka, Zambia. 8. Department of Haematology and Blood Transfusion, College of Medicine of the University of Lagos, Lagos, Nigeria. 9. Muelmed Hospital, Pretoria, South Africa. 10. Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa. 11. Global Child Health Group, Emma Children's Hospital/Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands Department of Pediatric Intensive Care, Emma Children's Hospital/Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands.
Abstract
OBJECTIVES: Limited availability of viral load (VL) monitoring in HIV treatment programmes in sub-Saharan Africa can delay switching to second-line ART, leading to the accumulation of drug resistance mutations (DRMs). The objective of this study was to evaluate the accumulation of resistance to reverse transcriptase inhibitors after continued virological failure on first-line ART, among adults and children in sub-Saharan Africa. METHODS: HIV-1-positive adults and children on an NNRTI-based first-line ART were included. Retrospective VL and, if VL ≥1000 copies/mL, pol genotypic testing was performed. Among participants with continued virological failure (≥2 VL ≥1000 copies/mL), drug resistance was evaluated. RESULTS: At first virological failure, DRM(s) were detected in 87% of participants: K103N (38.7%), G190A (21.8%), Y181C (20.2%), V106M (8.4%), K101E (8.4%), any E138 (7.6%) and V108I (7.6%) associated with NNRTIs, and M184V (69.7%), any thymidine analogue mutation (9.2%), K65R (5.9%) and K70R (5.0%) associated with NRTIs. New DRMs accumulated with an average rate of 1.45 (SD 2.07) DRM per year; 0.62 (SD 1.11) NNRTI DRMs and 0.84 (SD 1.38) NRTI DRMs per year, respectively. The predicted susceptibility declined significantly after continued virological failure for all reverse transcriptase inhibitors (all P < 0.001). Acquired drug resistance patterns were similar in adults and children. CONCLUSIONS: Patterns of drug resistance after virological failure on first-line ART are similar in adults and children in sub-Saharan Africa. Improved VL monitoring to prevent accumulation of mutations, and new drug classes to construct fully active regimens, are required.
OBJECTIVES: Limited availability of viral load (VL) monitoring in HIV treatment programmes in sub-Saharan Africa can delay switching to second-line ART, leading to the accumulation of drug resistance mutations (DRMs). The objective of this study was to evaluate the accumulation of resistance to reverse transcriptase inhibitors after continued virological failure on first-line ART, among adults and children in sub-Saharan Africa. METHODS:HIV-1-positive adults and children on an NNRTI-based first-line ART were included. Retrospective VL and, if VL ≥1000 copies/mL, pol genotypic testing was performed. Among participants with continued virological failure (≥2 VL ≥1000 copies/mL), drug resistance was evaluated. RESULTS: At first virological failure, DRM(s) were detected in 87% of participants: K103N (38.7%), G190A (21.8%), Y181C (20.2%), V106M (8.4%), K101E (8.4%), any E138 (7.6%) and V108I (7.6%) associated with NNRTIs, and M184V (69.7%), any thymidine analogue mutation (9.2%), K65R (5.9%) and K70R (5.0%) associated with NRTIs. New DRMs accumulated with an average rate of 1.45 (SD 2.07) DRM per year; 0.62 (SD 1.11) NNRTI DRMs and 0.84 (SD 1.38) NRTI DRMs per year, respectively. The predicted susceptibility declined significantly after continued virological failure for all reverse transcriptase inhibitors (all P < 0.001). Acquired drug resistance patterns were similar in adults and children. CONCLUSIONS: Patterns of drug resistance after virological failure on first-line ART are similar in adults and children in sub-Saharan Africa. Improved VL monitoring to prevent accumulation of mutations, and new drug classes to construct fully active regimens, are required.
Authors: Philip J Palumbo; Jessica M Fogel; Sarah E Hudelson; Ethan A Wilson; Stephen Hart; Laura Hovind; Estelle Piwowar-Manning; Carole Wallis; Maria A Papathanasopoulos; Mariza G Morgado; Shanmugam Saravanan; Srikanth Tripathy; Joseph J Eron; Joel E Gallant; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Jose H Pilotto; Johnstone Kumwenda; Victor Akelo; Sheela V Godbole; Breno R Santos; Beatriz Grinsztejn; Ravindre Panchia; Suwat Chariyalertsak; Joseph Makhema; Sharlaa Badal-Faesen; Ying Q Chen; Myron S Cohen; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2018-04-15 Impact factor: 3.731
Authors: Pascale Ondoa; Andrea A Kim; T Sonia Boender; Guoqing Zhang; Stefanie Kroeze; Jeffrey Wiener; Tobias Rinke de Wit; John Nkengasong Journal: AIDS Res Hum Retroviruses Date: 2020-08-27 Impact factor: 2.205
Authors: F Parker Hudson; Lloyd Mulenga; Andrew O Westfall; Ranjit Warrier; Aggrey Mweemba; Michael S Saag; Jeffrey Sa Stringer; Joseph J Eron; Benjamin H Chi Journal: Antivir Ther Date: 2019
Authors: V Carnimeo; I A Pulido Tarquino; S Fuentes; D Vaz; L Molfino; N Tamayo Antabak; R M Cuco; A Couto; S Lobo; J de Amaral Fidelis; J S Mulassua; I Ciglenecki; T Ellman; B Schramm Journal: JAC Antimicrob Resist Date: 2021-05-12